Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…
New Economist Impact Study Finds Only 22% of Enterprises Believe Their IT Infrastructure is Ready for AI
85% of global enterprises are actively using or testing generative AI in…
Ten Years of Impact: The SANY Foundation’s Enduring Mission in Philanthropy
SHANGHAI, Nov. 14, 2024 /PRNewswire/ -- 2024 marks the eleventh year since…
HTX Ventures: Crypto’s Impact on 2024 U.S. Election Dynamics
SINGAPORE, Nov. 5, 2024 /PRNewswire/ -- HTX Ventures, the global investment division…